ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
From Label-Free Multiphoton Imaging to Pathological Reports: A Vision-Language Breast Cancer Margin Pathological Diagnosis System.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Margin pathological assessment provides critical feedback for breast-conserving surgery, whereas H&E-stained histopathology focuses on residual tumor and may cause unnecessary resections. Label-free multiphoton microscopy (MPM) reveals tumor-associated collagen signatures (TACS) at the margin, offering a prognostically relevant diagnostic information. However, limited familiarity of novel MPM images by pathologists has prevented its integration into diagnostic workflows. Here, we introduce MarginPath, a Margin Pathological diagnosis system built on an MPM-language model that requires only a single label-free section. By integrating MPM-derived TACS with virtual H&E diagnostic information, MarginPath provides a multimodal diagnostic report, including: (i) a MPM image and corresponding virtual H&E image, (ii) a TACS-based pixel-level margin-status heatmap, and (iii) detailed natural-language diagnostic descriptions of tumor margin microenvironment. Validated on 158 invasive breast cancer specimens, MarginPath outperforms existing pathology vision-language models in margin diagnosis and can be extended into a question-answering system, enhancing both clinical decision-support and patient communication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.